Cerebroprotective Potential of Andrographolide Nanoparticles: In silico and In vivo Investigations.


Journal

Drug research
ISSN: 2194-9387
Titre abrégé: Drug Res (Stuttg)
Pays: Germany
ID NLM: 101602406

Informations de publication

Date de publication:
11 Jul 2024
Historique:
medline: 12 7 2024
pubmed: 12 7 2024
entrez: 11 7 2024
Statut: aheadofprint

Résumé

Ischemic stroke remains the leading cause of death and disability, while the main mechanisms of dominant neurological damage in stroke contain oxidative stress and inflammation. Docking studies revealed a binding energy of - 6.1 kcal/mol for AG, while the co-crystallized ligand (CCl) exhibited a binding energy of - 7.3 kcal/mol with NOS. AG demonstrated favourable hydrogen bond interactions with amino acids ASN A:354 and ARG A:388 and hydrophobic interactions with GLU A:377. Molecular dynamics simulations throughout 100 ns indicated a binding affinity of - 27.65±2.88 kcal/mol for AG, compared to - 18.01±4.02 kcal/mol for CCl. These findings suggest that AG possesses a superior binding affinity for NOS compared to CCl, thus complementing the stability of NOS at the docked site.AG has limited applications owing to its low bioavailability, poor water solubility, and high chemical and metabolic instability.The fabrication method was employed in the preparation of AGNP, SEM analysis confirmed spherical shape with size in 19.4±5 nm and investigated the neuroprotective effect in cerebral stroke rats induced by 30 min of carotid artery occlusion followed by 4 hr reperfusion, evaluated by infarction size, ROS/RNS

Identifiants

pubmed: 38991529
doi: 10.1055/a-2345-5396
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

There are no conflicts of interest with other people or organizations that could inappropriately influence or bias the content of the paper.

Auteurs

Lakshmi Charitha Rudrala (LC)

Department of Pharmacology, SKU College of Pharmaceutical Sciences, S. K. University, Anantapur, India.

Ranadheer Reddy Challa (RR)

Department of Formulations and Development, Quotient Sciences, Garnet Valley, PA, USA.

Sibbala Subramanyam (S)

Department of Pharmaceutical Sciences, School of Biotechnology and Pharmaceutical Sciences, Vignan's Foundation for Science, Technology & Research (Deemed to be University), Guntur, India.

Sampath Ayyappa Gouru (S)

Aura Biosciences Inc., Boston, USA.

Gagandeep Singh (G)

Section of Microbiology, Central Ayurveda Research Institute, Jhansi, Uttar Pradesh, India.

N V L Sirisha Mulukuri (NVL)

Department of Pharmacognosy, Nitte College of Pharmaceutical Sciences, Bangalore, India.

Praveen Kumar Pasala (PK)

Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research, JNTUA, Anantapur, India.

Prasanth Sree Naga Bala Krishna Dintakurthi (PSNBK)

School of Pharmacy & Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS), Hyderabad, India.

Somasekhar Gajula (S)

Department of Pharmacology, SKU College of Pharmaceutical Sciences, S. K. University, Anantapur, India.

Mithun Rudrapal (M)

Department of Pharmaceutical Sciences, School of Biotechnology and Pharmaceutical Sciences, Vignan's Foundation for Science, Technology & Research (Deemed to be University), Guntur, India.

Classifications MeSH